Treatment for dry eye syndrome

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is an improved formulation for the treatment of the underlying inflammatory processes that cause dry eye syndrome.
Through the oral administration of a blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1), the root causes of dry eye syndrome are addressed.
Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.
Although this particular formulation is described in connection with the treatment of human dry eye syndrome, it is also intended that the formulation and could also be used for the treatment of dry eye syndrome among various animals, such as dogs.
[It is known that various animals having, for the most part, a similar physiology of the eye to the human eye also suffer from dry eye syndrome.
Accordingly, the formulation of the present invention is also effective at treating dry eye syndrome among these various animals.
Although, the effective amounts needed for the treatment vary between humans and animals, one skilled in the art can determine the differences in the effective amounts based on the particular size of the animals.
] In a first preferred embodiment, the formulation includes the following components along with the preferred ranges of amounts for each component: Vitamin A (as retinyl palmitate) 1000 IU (or a range of 500 IU to 1600 IU) Vitamin C 100 mg (or a range of 30 mg to 400 mg) (as Calcium ascorbate and Ascorbyl Palmitate) Vitamin E (as mixed tocopherols oil) 32 IU (or a range of 10 IU to 200 IU) Vitamin B6 (as pyridoxal-5-phosphate) 8 mg (or a range of 4 mg to 30 mg) Magnesium (as magnesium sulfate) 20 mg (or a range of 10 mg to 200 mg) Black currant seed oil 00 mg (or a range of 400 to 2500 mg) Cod liver oil 2 mg (or a range of 1 mg to 7 mg) Mucopolysaccarides (mucin complex) 250 mg (or a range of 50 mg to 400 mg) Turmeric (Curcuma longa) extract (root) 100 mg (or a range of 20 mg to 300 mg) Lactoferrin 10 mg (or a range of 5 mg to 200 mg) In a second preferred embodiment, other components can be included to impart additional features to the formulation